GRAIL announced results from its NHS-Galleri trial showing that annual Galleri blood tests significantly reduce late-stage (Stage IV) cancer diagnoses by 22% in the second screening round and 26% in the third. The test also increased early-stage (Stage I-II) cancer detection by 16% when added to standard screening and reduced emergency cancer diagnoses by 25%. These findings highlight Galleri's potential to improve early cancer detection and reduce advanced cancer cases, which could lead to better patient outcomes. GRAIL will discuss these results further at the 2026 ASCO Annual Meeting.
The Hanover Insurance Group announced a quarterly dividend of $0.95 per common share, payable on June 26, 2026, to shareholders of record as of June 12, 2026. This dividend reflects the company's ongoing commitment to returning value to shareholders....
Alexandria Real Estate Equities announced a quarterly cash dividend of $0.72 per common share for Q2 2026, payable on July 15 to shareholders of record as of June 30. This dividend matches the previous quarter's payout and supports the company's stro...
Parex Resources has finalized its acquisition of Frontera Energy's Colombian exploration and production assets for $500 million, making it the largest independent oil and gas producer in Colombia. The deal, funded by senior unsecured notes and debt a...
zSpace, Inc. has converted over $12 million of its outstanding debt into equity through agreements with two lenders, significantly improving its financial position. Fiza Investments converted about $10 million in debt into common and preferred stock ...
Nvidia unveiled new ARM-based hardware at Computex 2026, including the "Vera" CPU designed for AI and data centers. Jim Cramer praised the move, calling it a major positive for ARM Holdings, whose stock has surged over 200% this year. Nvidia is shift...
